The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has surged to 1.3 billion people, marking a 143% increase over the past three decades. By 2050, projections indicate that this number could rise to 1.8 billion, primarily due to rising obesity and blood sugar levels.